Taking people in United StatesPhase 3

Testing a new weight-loss drug for adults with obesity already on GLP-1 drugs

Tests maridebart cafraglutide in adults with obesity who switch from GLP-1 drugs.

Plain-language title generated from the registry record
Registry title: Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Key facts

Where: Austin, Baton Rouge, Beaver, Canton, Chandler, Chickasha, Chula Vista, DeSoto, Duncansville, Edinburg, Gainesville, Hialeah, Houston, Johns Creek, Kapolei, Las Vegas, Lenexa, Margate, McAllen, McKinney, Meridian, Miami, Missoula, Morehead City, Mt. Dora, New York, North Richland Hills, Oklahoma City, Orlando, Palm Springs, Pelham, Port Orange, Raleigh, Redmond, Rialto, Ridgeland, Rochester, San Antonio, San Diego, Santa Ana, Skokie, Southfield, Springfield, Sun City, Sun City West, The Villages, Tomball, Troy, Union City, Wilmington, and Woodstock, United StatesSee the 56 sites
Phase: Phase 3

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

Are you between 18 and 99 years old?

Source: NCT07575399, who can take part

Where in United States

Pinnacle Clinical Research GeorgetownAustin, United StatesTaking people
Pennington Biomedical Research CenterBaton Rouge, United StatesTaking people
Heritage Valley Multispecialty Group, IncBeaver, United StatesTaking people
East Coast Institute for ResearchCanton, United StatesTaking people
Arizona Clinical TrialsChandler, United StatesTaking people
Epic Medical Research - OklahomaChickasha, United StatesTaking people
Peninsula Research AssociatesChula Vista, United StatesTaking people
Epic Medical Research - DeSotoDeSoto, United StatesTaking people
Altoona Center For Clinical ResearchDuncansville, United StatesTaking people
South Texas Research InstituteEdinburg, United StatesNo longer taking part
University of Florida Department of MedicineGainesville, United StatesTaking people
AGA Clinical TrialsHialeah, United StatesTaking people
Biopharma Informatic, LLCHouston, United StatesTaking people
Research Physicians Network, LLCHouston, United StatesTaking people
NSC ResearchJohns Creek, United StatesTaking people
Mel A. Ona, M.D., IncorporatedKapolei, United StatesTaking people
Excel Clinical ResearchLas Vegas, United StatesTaking people
Johnson County Clinical TrialsLenexa, United StatesTaking people
South Florida Clinical ResearchMargate, United StatesTaking people
Biopharma Informatic-McAllenMcAllen, United StatesTaking people
Texas Institute of CardiologyMcKinney, United StatesTaking people
Solaris Clinical ResearchMeridian, United StatesTaking people
New Horizon Research CenterMiami, United StatesTaking people
Research Institute of South FloridaMiami, United StatesTaking people
Montana Medical ResearchMissoula, United StatesTaking people
Centricity Research Morehead City SpecialtyMorehead City, United StatesTaking people
Adult Medicine of Lake CountyMt. Dora, United StatesTaking people
Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
North Hills Medical ResearchNorth Richland Hills, United StatesTaking people
Lynn Health Science InstituteOklahoma City, United StatesTaking people
Clinical Neuroscience SolutionsOrlando, United StatesTaking people
Florida Institute for Clinical ResearchOrlando, United StatesTaking people
Desert Oasis Healthcare Medical GroupPalm Springs, United StatesTaking people
Cahaba Research, Inc.Pelham, United StatesTaking people
Progressive Medical ResearchPort Orange, United StatesTaking people
Accellacare of RaleighRaleigh, United StatesTaking people
Eastside Research Associates Health ResearchRedmond, United StatesTaking people
Inland Empire Liver FoundationRialto, United StatesTaking people
Sky Integrative Medical CenterRidgeland, United StatesTaking people
Rochester Clinical ResearchRochester, United StatesTaking people
American Research CorporationSan Antonio, United StatesTaking people
Gastroenterology Clinic of San Antonio PASan Antonio, United StatesTaking people
VIP TrialsSan Antonio, United StatesTaking people
Apex Clinical ResearchSan Diego, United StatesTaking people
Southern California Clinical ResearchSanta Ana, United StatesTaking people
Endeavor HealthSkokie, United StatesTaking people
Great Lakes Research InstituteSouthfield, United StatesTaking people
Central Illinois Diabetes and Clinical Research, a Division of Prairie Education and Research CooperSpringfield, United StatesTaking people
Epic Medical Research - Sun CitySun City, United StatesTaking people
Clinical Research Institute of Arizona, LLCSun City West, United StatesTaking people
Charter Research The VillagesThe Villages, United StatesTaking people
Northwest Houston Heart CenterTomball, United StatesTaking people
Arcturus Healthcare, Public Limited Company, Troy Internal Medicine Research DivisionTroy, United StatesTaking people
Rophe Adult and Pediatric Medicine/Sky Clinical Research Network GroupUnion City, United StatesTaking people
Accellacare Research of WilmingtonWilmington, United StatesTaking people
North Georgia Clinical ResearchWoodstock, United StatesTaking people

Questions to ask the study team

How often do I need to come in, and for how long each time?
Are travel costs paid?
Can I keep my own doctor?
What happens if I want to stop?

Print a page for my doctor

Trial details

Who runs it: Amgen
Trial code: NCT07575399
Record updated: 6 November 2026
Original description: Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.Read full original descriptionShow less
A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1 Receptor Agonists to Maridebart Cafraglutide in Adult Participants With Obesity or Overweight
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
Inclusion: Body Mass Index (BMI) ≥ 25 at screening; Weight loss of ≥ 10% on weekly GLP-1 RA; Stable body weight; Stable dose of GLP-1RA; Stable gastrointestinal (GI) tolerability; Contraception for females; Willingness to follow trial procedures for the duration of the trial.
Exclusion: Previous or planned surgical, endoscopic or device-based treatment for obesity; Previous participation in a Maridebart Cafraglutide trial; Obesity induced by other endocrine disorders (ex: Cushing's syndrome); History of malignancy; Type 1/Type 2 diabetes mellitus (DM); Family or personal history of medullary thyroid cancer.
ClinicalTrials.gov NCT07575399